1 / 19

Practical issues related to pandemic deployment of antivirals

Practical issues related to pandemic deployment of antivirals. Jonathan Van-Tam, MBE, DM, FFPH, FRIPH, Professor of Health Protection. Maiden Castle, Dorset, 450 BC. Pre-pandemic vaccine?. Layered defence offers greatest chance of overall protective effect. Antivirals. Antibiotics.

zlata
Download Presentation

Practical issues related to pandemic deployment of antivirals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Practical issues related to pandemic deployment of antivirals Jonathan Van-Tam, MBE, DM, FFPH, FRIPH, Professor of Health Protection

  2. Maiden Castle, Dorset, 450 BC

  3. Pre-pandemic vaccine? Layered defence offers greatest chance of overall protective effect Antivirals Antibiotics Public Health Measures Pandemic Vaccine

  4. Public health purpose of antiviral use • Protection of HCWs • Protection of workers within CNI • Population level usage • Can priority groups be identified in advance? • Would priority groups be ethically and publicly acceptable?

  5. Desired clinical or epidemiological endpoint alters strategy chosen

  6. Duration of illness:Influenza-infected patients, n=475 p=0.02 for placebo vsoseltamivir 75 mg p=0.01 for placebo vsoseltamivir 150 mg 116.5 29.1 h 34.7 h 87.4 81.8 Median Duration of illness (h) n=161 n=158 n=156 Placebo 75 mg 150 mg Nicholson et al. Lancet 2000; 355: 1845-50.

  7. Severity of illness:Influenza-infected patients, n=475 943 18% 25% 773 709 Median Total Symptom Score (AUC) n=158 n=156 n=161 Placebo 75 mg 150 mg p<0.01 for placebo vs oseltamivir 75 mg p<0.003 for placebo vs oseltamivir 150 mg Nicholson et al. Lancet 2000; 355: 1845-50.

  8. Early oral oseltamivir for influenza (adults)Effect on antibiotic use and hospitalizations (meta-analysis; n=3564) Placebo Oseltamivir LRT complicationsleading to use of antibiotics All hospitalizations 50% 55% 52% 59% Patients (%) 62% * * 61% ** *p<0.001 vs placebo **p<0.05 vs placeboLRT=lower respiratory tract Kaiser et al. Arch Intern Med 2003;163:1667–72

  9. Early oral oseltamivir for influenza (children)Effect on antibiotic use and complications (n=252) 50 40 30 20 10 0 placebo oseltamivir 24% 40% * 44% Patients (%) ** Complications Otitis media Antibiotics *p<0.05**p<0.01 vs placebo Whitley et al. Pediatr Infect Dis J 2001;20:127–33

  10. Cohort studies: Improved outcomes with oseltamivir Bowles et al. J Am Geriatr Soc. 2002;50:608-16 Reduction in complications/hospitalization in treated nursing home residents Nordstrom et al. Curr Med Res Opin. 2005;21:761-8 26% reduction in hospitalization in patients with ILI treated with oseltamivir McGeer et al. Clin Infect Dis. 2007;45:1568-75 70% reduction in mortality in hospitalized adults Lee et al. Antivir Therapy. 2007; 12:501-8 Shorter length of stay in hospitalized adults treated early Barr et al. Curr Med Res Opin. 2007;23:523-31 50% reduction in pneumonia in treated children

  11. Prevention of influenza in long term carezanamivir 10mg (2 puffs) o.d. in outbreak Ambrozaitis JADA 2005;6:367

  12. Earliest treatment is associated with maximum clinical benefit (open-label; n=1426) Time From Symptom Onset to Treatment (h) 12 24 0 36 –1.2 d –2.2 d –3.1 d –3.8 d Reduction of Illness Duration (Days) Compared With Intervention at 48 h Modelled time to treatment P < 0.0001. Aoki et al Journal of Antimicrobial Chemotherapy 2003: 51:123-129

  13. Operational framework for delivery: stockpiling • Secure storage, yet compatible with rapid delivery (local/regional equity in distribution) • Seasonal use too low to allow storage within community seasonal supply chain (true pandemic stockpile) • Choice of agents (licensed indications e.g. age, propensity for resistance, ease of use by patient, pack size in storage) • Choice of formulations (capsules in different sizes, diskhalers, suspension, dry active) • Timing of procurement – timing of replacement/rejuvenation

  14. Global usage of oseltamivir across influenza seasons * Influenza season reflected as 12 months of data (Sept –Aug)

  15. Stockpiling options (oseltamivir) • 30, 45 and 75 mg capsules • Long shelf-life • Flexibility with dosing possible • Pediatric Oral Suspension • Short shelf-life • Active Pharmaceutical Ingredient (API) • Needs preparation – time; expertise; equipment

  16. Management of expiry of oseltamivir government stockpiles • Oseltamivir has an approved shelf life of 5 years in most markets • Recent extension to 7 years in US; similar data filed elsewhere • Internal longer term stability data and governments can choose to extend the shelf life of their stockpiles, based on these data • Roche is developing a method for extracting the active ingredient from expiring capsules for reprocessing into new capsules, thus ‘re-setting’ the clock on existing procurement

  17. Operational framework for delivery: distribution • Defined access points (general practices, community pharmacies) • Other options include: • Telephone diagnosis and remote prescribing • Influenza Tx centres? • Home visiting teams? • Pre-issue? • Operational research/simulations may be needed to determine throughput and most efficient approach

  18. Operational framework for delivery: usage • Timing of release from stockpile into HC system • Equitable distribution by locality and region (regional and local positioning of stockpiles) • Familiarity of HCWs with drugs themselves (clinical recognition of treatment success/failure) • Devolution of prescribing to professions allied to medicine (training and familiarity) • GPs reserved for children and complicated cases • Protocols/treatment guidance and ability to modify rapidly • Patient consulting behaviour (e.g. Ross et al, Comm Dis Publ Health 2000;3:256-60)

  19. Conclusions • Decision to stockpile neuraminidase inhibitor is central to an overall package of pandemic preparedness measures • Ultimate benefit depends not only on choice of strategy but slickness/sophistication of execution • Large number of practical issues that together require consideration to build an effective operational strategy • As bad to procure antivirals and then fail in delivery, than to have none at all Jonathan Van-Tam

More Related